# Vesalius Biocapital

Vesalius Biocapital is a Private Equity based in Luxembourg, Luxembourg.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Luxembourg, Luxembourg
- **Region:** Europe
- **Address:** Luxembourg
- **Founded:** 2007
- **Assets under management:** Undisclosed
- **Website:** vesaliusbiocapital.com
- **LinkedIn:** https://linkedin.com/company/vesalius-biocapital

## Regulatory record

- **Reports private funds:** No

## About

Vesalius BioCapital Partners is a venture capital firm founded in 2007 in Strassen, Luxembourg. It invests in human health companies through various funds, having made 65 investments.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- Brussels, Belgium
- Toronto, Canada

## People

- Stéphane Verdood — Managing Partner
- Anne Portwich — Partner

## Questions

### Who runs investment decisions at Vesalius Biocapital?

Managing Partner Stéphane Verdood, a co-founder, leads the investment committee. He works alongside Partner Anne Portwich and a team of investment professionals based in Luxembourg and Brussels. The firm integrates operating partners with pharmaceutical R&D backgrounds into the due-diligence process, giving clinical judgment equal weight to financial analysis.

### How does Vesalius Biocapital source proprietary deal flow?

The firm leans heavily on direct relationships with European research universities and academic medical centers, particularly in Belgium, France, Germany, and the Netherlands. Many portfolio companies originate as university spin-outs where Vesalius can structure the first institutional round. The Toronto office adds a second sourcing channel by identifying North American platforms seeking a European clinical-development partner.

### What investment stages does Vesalius Biocapital typically target?

Vesalius invests from seed and Series A through growth-stage rounds, occasionally participating in later-stage crossovers when a portfolio company approaches a clinical or regulatory inflection point. The firm can lead, co-lead, or syndicate, and has supported companies from preclinical proof-of-concept through Phase II clinical data readouts.

### Does Vesalius Biocapital participate in fund commitments or only direct deals?

The firm makes direct equity investments into life sciences companies. It does not operate a fund-of-funds program, though its limited partners include fund-of-funds vehicles such as the European Investment Fund. Vesalius structures its own flagship fund series for direct investing, with Vesalius Biocapital III closing in 2019.

### Which sectors does Vesalius Biocapital explicitly avoid?

Vesalius restricts itself to human life sciences — biopharma, medical devices, and diagnostics. It does not invest in healthcare IT, consumer wellness, provider services, or animal health. Within biopharma, the firm has shown a preference for small-molecule and biologic platforms over digital therapeutics.

### How does the Brussels-Toronto axis affect portfolio companies?

The Toronto office provides European portfolio companies with access to North American clinical-trial infrastructure, regulatory consultants, and co-investor relationships without requiring the firm to raise a separate US-dollar fund. This transatlantic structure is designed to help companies design FDA-acceptable trial protocols and open US investigative sites while still operating from a European cost base.

## Related profiles

- [Vesa Equity Investment](https://altss.com/profile/vesa-equity-investment)
- [Vesey Street Capital Partners](https://altss.com/profile/vesey-street-capital-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/vesalius-biocapital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology